A New Point-of-Care Indicator System for Dry Eye Syndrome

Auxano Diagnostics, LLC, a subsidiary of Auxano Biomedical, LLC, has announced
the application of the company`s breakthrough wound care technology to the
treatment of dry eye syndrome (DES) with the Auxano point-of-care indicator
system. Dry eye syndrome (DES) is a condition that affects millions of people
worldwide. According to the Centers for Disease Control (CDC), DES can be a
serious condition, which, if left untreated, can damage ocular structures.

Brian Windsor, Ph.D., Chief Technical Officer for Auxano Biomedical, said, "We
are excited that the advances of our wound care technology can be applied to the
treatment of DES and other ophthalmic diseases. Our point-of-care indicator
system has the potential to provide earlier and more accurate guidance to
millions of DES sufferers."

Market Dynamics

Primary ophthalmic disorders associated with inflammation currently affect over
20 million people in the US. The CDC reports that the most prevalent disorders
in this category include DES, age-related macular degeneration (AMD) and
proliferative diabetic retinopathy (PDR). According to Business Insights, the
ophthalmic pharmaceutical market registered sales of $13.5 billion in 2008.

A challenge encountered in the treatment and management of ophthalmic care is
the identification between acute and chronic inflammatory diseases that lead to
visual impairment. Currently, there are no diagnostics focused on inflammatory
eye disease, and the primary way to detect inflammation is through purely
empirical methods. Misdiagnosis can lead to additional tissue damage and
potential blindness.

A solution to proper discernment between inflammatory and non-inflammatory
conditions would result in early and correct guidance towards the appropriate
therapeutic regimen, effective tracking of treatment, enhanced patient
satisfaction, and improved outcomes.

Auxano`s system is a rapid point-of-care diagnostic indicator for ophthalmic
inflammatory diseases and has the potential to provide for accurate indications
of DES within minutes.

New Ophthalmic Focus for Auxano Diagnostics

Auxano Diagnostics has developed a similar point-of-care product for wound care
that is based on the efficient and accurate detection of active enzymes in
biological samples. This product provides detection of inflammation through
targeting matrix metalloproteinases (MMPs) in wound fluids that can be obtained
by non-invasive sampling techniques. This MMP indicator is in clinical trials
through a partnership with a global technology company with the expectation of a
CE mark in December 2009, followed by FDA 510(k) approval.

Auxano`s primary focus is the adaptation, optimization and commercialization of
the existing technology for acute and chronic inflammatory diseases of the eye,
in particular, dry eye syndrome. Initial data indicates positive results for
detecting physiologically relevant MMP levels in dry eye syndrome.

For more information go to www.maculardegenerationassociation.org